Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rep. Burgess Vows To Fight FDA Panel Conflict-Of-Interest Restrictions

This article was originally published in The Gray Sheet

Executive Summary

Relaxing conflict-of-interest restrictions for FDA advisory panels will be a top priority for Texas Republican Congressman Michael Burgess during the upcoming reauthorization of device and drug user fee programs, he said Sept. 26.

You may also be interested in...

Draft User Fee Bills Aim To Streamline And Strengthen Device Regs

Details on draft legislation circulating in the House and Senate.

Rep. Burgess Not Changing Conflict-Of-Interest Thinking Despite Advisory Committee Flap

Sponsor of bill that would loosen conflict of interest rules says requiring public release of financial disclosure documents, as one group suggested, may not require a legislative fix.

Flurries Of New Bills Advance Device Industry Interests In Congress

The first legislative salvos were launched last week in a battle that is sure to escalate in conjunction with device user fee reauthorization efforts next year.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts